Pharming price target raised to $39 from $30 at Oppenheimer
Oppenheimer raised the firm’s price target on Pharming (PHAR) to $39 from $30 and keeps an Outperform rating on the shares following quarterly ...
Pharming Group (PHGUF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Pharming Group (PHGUF) reports a 21% increase in full-year revenue, strategic Abliva acquisition, and positive financial outlook for 2025.
Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth
Q4 2024 Management View CEO Fabrice Chouraqui highlighted a strong performance in 2024 with revenue growth of 21% to $297 million, exceeding guidance. He emphasized RUCONEST's growth of 11% to $252 ...
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...
The Pharma Letter1d
Pharming reports revenue growth and strategic expansion in 2024
Dutch biopharma company Pharming (Euronext Amsterdam: PHARM) has reported a 21% increase in revenue for 2024, reaching $297 ...
Pharming Group to participate in March investor conference
Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of March: 37th Annual ...
ETF Daily News3d
Pharming Group (PHAR) Expected to Announce Earnings on Thursday
Pharming Group has a 52-week low of $6.65 and a 52-week high of $11.94. The stock has a market capitalization of $541.53 million, a P/E ratio of -30.62 and a beta of -0.10. Get Pharming Group alerts: ...
Pharming Group (NASDAQ:PHAR) Shares Gap Up – What’s Next?
Pharming Group (NASDAQ:PHAR – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $8.54, but opened at $9.06. Pharming Group shares last traded at $9.15, ...
Pharming Group Full Year 2024 Earnings: EPS Beats Expectations
Full Year 2024 Results Key Financial Results Revenue: US$297.2m (up 21% from FY 2023).
The National Law Review22d
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
Leiden, the Netherlands, February 20, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer ...
3 European Penny Stocks With Market Caps Over €300M
The European market has recently experienced a slight downturn, with the pan-European STOXX Europe 600 Index ending lower amid ongoing uncertainty about U.S. trade policy. Despite these challenges, ...
Nasdaq21d
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating ...